Pfizer Inc. (PFE)
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-year revenue guidance while slightly increasing the EPS guidance range. The new Chief Strategy and Innovation Officer may lead to changes in business development approach, although his hands may be tied by the debt burden in the near-term.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) closed at $27.66 in the latest trading session, marking a -1.32% move from the prior day.
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study
Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting disorder did not meet the main goal of a late-stage trial.
Pfizer: An Oversold Pharma Stock in Recovery
Some say the art of investing is the ability of catching falling knives. Pfizer Inc. (PFE, Financial) shares have sold off in 2023 and represent an attractive opportunity after having likely bottomed out.
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Billionaires don't necessarily need passive income, but they like to buy dividend stocks for the outsized returns they can provide. After falling a long way from its previous peak, Pfizer stock offers a mouth-watering dividend yield.
Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 11:20 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's kick off our discussion with Pfizer here. My name is Chris Shibutani.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.
Pfizer: Too Cheap To Miss Out
Pfizer's stock is currently trading below pre-pandemic levels, despite the record-breaking year it had in 2023 for FDA approvals and the significant acquisition of Seagen. Weak sentiment is likely explained by the significant risk of two best-selling products losing their exclusivity in 2026. Intrinsic value calculations suggest that the stock is 75% undervalued, meaning that the biggest risk is likely factored in.
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Pfizer has been trimming expenses as it adjusts to a decline in demand related to COVID-19. It recently announced a new cost-cutting plan that will save $1.5 billion in expenses.
